tetano
Editor, Senior Moderator
Eur Respir Rev
. 2022 Nov 29;31(166):220099.
doi: 10.1183/16000617.0099-2022. Print 2022 Dec 31.
Inhaled corticosteroids for the treatment of COVID-19
Mona Bafadhel[SUP] 1 [/SUP], Rosa Faner[SUP] 2 [/SUP], Camille Taillé[SUP] 3 [/SUP], Richard E K Russell[SUP] 4 [/SUP], Tobias Welte[SUP] 5 [/SUP], Peter J Barnes[SUP] 6 [/SUP], Alvar Agustí[SUP] 7 [/SUP]
Affiliations
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused severe illness and mortality for millions worldwide. Despite the development, approval and rollout of vaccination programmes globally to prevent infection by SARS-CoV-2 and the development of coronavirus disease 2019 (COVID-19), treatments are still urgently needed to improve outcomes. Early in the pandemic it was observed that patients with pre-existing asthma or COPD were underrepresented among those with COVID-19. Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19. This review summarises the evidence supporting the beneficial effects of ICS on outcomes in patients with COVID-19 and explores the potential protective mechanisms.
. 2022 Nov 29;31(166):220099.
doi: 10.1183/16000617.0099-2022. Print 2022 Dec 31.
Inhaled corticosteroids for the treatment of COVID-19
Mona Bafadhel[SUP] 1 [/SUP], Rosa Faner[SUP] 2 [/SUP], Camille Taillé[SUP] 3 [/SUP], Richard E K Russell[SUP] 4 [/SUP], Tobias Welte[SUP] 5 [/SUP], Peter J Barnes[SUP] 6 [/SUP], Alvar Agustí[SUP] 7 [/SUP]
Affiliations
- PMID: 36450371
- DOI: 10.1183/16000617.0099-2022
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused severe illness and mortality for millions worldwide. Despite the development, approval and rollout of vaccination programmes globally to prevent infection by SARS-CoV-2 and the development of coronavirus disease 2019 (COVID-19), treatments are still urgently needed to improve outcomes. Early in the pandemic it was observed that patients with pre-existing asthma or COPD were underrepresented among those with COVID-19. Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19. This review summarises the evidence supporting the beneficial effects of ICS on outcomes in patients with COVID-19 and explores the potential protective mechanisms.